Industrial manufacturer IDEX (IEX) is set to release its quarterly results Wednesday morning, with Wall Street anticipating a slight revenue increase. The report comes amid a broader rally in fluid and gas handling stocks.
IDEXX Laboratories announces a planned CEO transition for 2026 alongside the launch of its flagship AI veterinary imaging platform, signaling a dual focus on leadership continuity and technological innovation in the competitive animal health diagnostics market.
IDEXX Laboratories (IDXX) reported robust double-digit growth for Q4 2025, driven by record placements of its premium diagnostic instruments and expanding test utilization. While acknowledging persistent softness in U.S. veterinary visit volumes, the company outlined a confident initial 2026 forecast, banking on its innovation pipeline and the transformative impact of its inVue Dx system.
IDEXX Laboratories reports robust fourth-quarter and full-year 2025 results, with double-digit revenue growth fueled by record instrument placements and strategic innovations like InVue DX and CancerDx. The company provides a confident outlook for 2026, targeting continued organic growth despite sector headwinds.
U.S. stock futures pointed to a lower open Monday as investors braced for a flood of corporate earnings and crucial labor market reports that could sway Federal Reserve policy expectations.
